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We read with interest the recent article by Wang and Liu [1],
describing their experience with rituximab (RTX) in 6 systemic
lupus erythematosus (SLE)-associated antiphospholipid syndrome
(APS) patients. These data support the idea that, in line with
previous sporadic cases reported in literature, RTX at different
regimens is able to reduce thrombotic recurrences and to improve
SLE activity, with an overall good safety profile. Moreover, theyemographic and clinical characteristics of the patients reported in our case seri
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72/& 2016 Elsevier Inc. All rights reserved.confirm the disappearance/decrease of titer of antiphospholipid
antibodies after RTX [1].
Here we report our monocentric experience of seven patients
treated with repeated courses of RTX at standard regimen (Table).
Our data confirm in part those of Wang, but there are also some
concerns. Among 455 patients of our Lupus Clinic, we retrieved 69
SLE-associated APS cases. Eight patients were treated with RTX,
while seven of them with repeated standard low-dose infusions
(the patient treated only once was excluded from this case series).
In our experience, RTX reduced the incidence of thrombotic
relapses in almost all patients (median follow-up ¼ 36 months,
range: 12–48) (Table). Indeed, 6/7 patients had APS clinical
remission (i.e., no thrombotic events) after RTX (Fig. A). Only one
patient (ID 4) relapsed after 6 months of treatment and his clinicales
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Fig. (A) Kaplan–Meier of relapse-free survival from recurrent thrombotic events in the 7 patients with SLE-associated APS. (B) Variation in SLEDAI of 7 patients of our cohort.
SLEDAI score was calculated before each rituximab treatment and at the last follow-up. The red line indicates the median SLEDAI value. (For interpretation of the references
to color in this figure legend, the reader is referred to the web version of this article.)
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Seminars in Arthritis and Rheumatism ] (2016) ]]]–]]]2course was catastrophic, with several thrombotic episodes despite
adequate anticoagulation and repeated cycles of RTX (Table).
Interestingly, he was the only patient in whom the indication
for RTX treatment was recurrent thrombosis despite good
anticoagulation and good control of SLE activity. In line with
the literature [1], RTX was able to reduce SLE activity in our
patients: the median SLEDAI before RTX was 10 (range: 4–14)
and after 6 months, from the last treatment, was 4 (range: 2–6;
Fig. B).
Regarding the treatment-related toxicity, only one patient
developed pneumonia 2 months after RTX treatment and
promptly responded to antibiotic therapy. The same patient
underwent other three retreatments with RTX at low dose, with-
out any other complication. Treatment-related hematologic toxi-
city was almost absent and all patients presented a reduction of
B-lymphocytes, without appreciable clinical symptoms.
In our cohort, the indication for the first RTX treatment was APS
activity only for one patient (ID 4), while in the remaining patients
the indication was SLE activity. These data are quite different from
those reported by Wang, who described that almost all the patients
had recurrent thrombotic events despite adequate anticoagulation,
thus requiring RTX treatment. The data of the literature are poor
and conflicting, since 5/10 patients required RTX for SLE activity,
and the others for recurrent thrombotic events [1].
Unlike the Wang cohort, all the patients followed at our
dedicated center were treated with a standardized protocol: induc-
tion treatment with RTX 1000 mg twice/2 weeks apart, and main-
tenance with low dose of RTX (500 mg). A similar infusion scheme
has been already successfully proposed in Granulomatosis with
Polyangiitis, showing a low rate of relapses [2]. A limitation of our
work is the variable time interval between the retreatments;
indeed, 5/7 patients were retreated after 6 months from the
induction infusion, while two patients (IDs 1 and 6) were retreated,
respectively, at 18 and 36 months. Only two patients were retreated
at 12 months (IDs 1 and 4), while the others received a second RTX
retreatment after 18 months (ID 3), 30 months (ID 5), 36 months (ID
1), and 42 months (ID 6) (Table).
Finally, we did not observe a disappearance of lupus antic-
oagulant and/or modifications of the titer of anticardiolipin anti-
bodies, differently from what reported by Wang and Liu [1].
RTX is emerging as a potential weapon in primary APS [3] and,
despite the failure of the registrative trials, it is a good option in
clinical practice for SLE patients who are refractory or intolerant to
conventional therapies [4]. Despite this, poor data are available onthe correct usage and the potential usefulness of RTX in secondary
forms of APS, associated with SLE. This kind of patients often
needs a combination of immunosuppressive and anticoagulant
treatments for the control of both the conditions, and RTX could be
an important alternative in resistant or active patients. Also in our
case series (the largest reported in literature), RTX has confirmed
its efficacy in preventing recurrent thrombosis in SLE-associated
APS patients. However, unlike Wang’s report, we have treated
our patients for their SLE activity, and not for the recurrence of
the thrombotic events; interestingly, we have successfully applied
a standard protocol with repeated low doses of RTX for the
retreatments, with a persistent clinical response, and a good safety
profile.
More prospective data with largest cohort of patients are
necessary to establish the right indication and the better regimen
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